Method of treating cancer using a caspase-4 inhibitor

Abstract

The present invention relates to the use as a biomarker of the active form of a human caspase protein, preferably the human caspase-4 or caspase-1, or of the active form of the protein encoded by an orthologue gene of the human caspase protein, preferably by an orthologue gene of the human caspase-4, for example the murine caspase-11 protein, in a method of diagnosis and/or prognosis and/or of monitoring the progression of a tumor, particularly lung cancer.

Claims

1. A method of treating a tumor in a subject, said method comprising: (a) determining the level of the active form of human caspase-4 (SEQ ID NO:1) in a sample isolated from the subject; (b) selecting the subject with an increased level of activated form of human caspase-4 when compared to a normal control; and (c) administering a specific inhibitor of an active form of human caspase-4 protein (SEQ. ID NO:1), and said inhibitor is a synthetic peptide selected from the group consisting of Ac-Tyr-Val-Ala-Asp-CHO (y-VAD-CHO) and Ac-Tyr-Val-Ala-Asp-CMK (Ac-Y-VAD-cmk), and wherein the tumor is a lung cancer.

2. The method according to claim 1, wherein the lung cancer is a lung carcinoma.

3. The method according to claim 1, further comprising determining the level of at least one additional tumor marker.

4. The method of claim 3, wherein the additional marker is a proinflammatory cytokine effector.

5. The method of claim 1, wherein the sample is a biological fluid, a cell sample or a tissue sample.

6. The method according to claim 1, wherein the human caspase-4 protein has an active portion having the amino acid sequence GILEGICGTV HDEKKPDVLL YDTIFQIFNN RNCLSLKDKP KVIIVQACRG (SEQ ID NO: 15).

Description

FIGURES

(1) FIG. 1. Experimental protocol of lung cancer induction in mice.

(2) FIG. 2. Analysis of lung cryosections through hematoxylin & eosin staining (H&E) (FIG. 2A), Ki-67 (FIG. 2B), and K-Ras (FIG. 2C). These lung sections were obtained from mice with lung cancer treated with the carcinogen NMU. (FIG. 2D) Quantification of tumor growth (expressed as tumor area/total area) in the lung of mice treated with NMU. Data are expressed as mean±SEM.

(3) FIG. 3. The active form of caspase-11 (p20 kDa) is present at different time points in the lung of mice with cancer, compared to naïve (untreated) mice that show only the inactive form (p46 kDa).

(4) FIG. 4. A. Tumor growth in C57Bl/6 mice vs. 129Sv mice (A); B. lung cancer growth in C57Bl/6 mice treated with an antibody (Ab) neutralizing the activity of IL-1α, compared to control mice (CTR).

(5) FIG. 5. Activation of caspase-1 (p20 kDa) in C57Bl/6 lung tumor-bearing mice (FIG. 5B), but not in naive (FIG. 5A) and 129Sv (FIG. 5C) mice.

(6) FIG. 6. Reduced tumor lesion in mice genetically deficient in caspase-1 and caspase-11 (caspase-1/11 ko) (***p<0,0005, ****p<0,0001) compared to C57Bl/6 animals (FIG. 6A), data comparable to that obtained in 129Sv animals (FIG. 6B). The pharmacological inhibition with a caspase-1 known specific inhibitor (Ac-Y-VAD-cmk, Sigma Aldrich, cat. N. SML-0429, Ac-Tyr-Val-Ala-Asp-Chloromethylketone; or y-VAD-CHO, Ac-Tyr-Val-Ala-Asp-CHO, Santa Cruz Technologies, USA, cat. N. sc-3069) reduced the tumor lesion in C57Bl/6 mice exposed to NMU (*p<0.05, **p<0.01) (FIG. 6C), even if this injury was not comparable to that observed in caspase-1/11 ko and 129Sv mice (FIG. 6D).

(7) FIG. 7. The administration of an antibody capable of inhibiting the activity of caspase-11 significantly reduced (*p<0.05) the tumor mass compared to control animals or animals treated with the control isotype (rabbit IgG).

(8) FIG. 8. Immunoprecipitation experiments. FIG. 8A) Caspase-11 binds AIM2 inflammasome complex; FIG. 8B) AIM2 binds to 8-OH-dG.

(9) FIG. 9. A. Presence of the precursor (p48-kDa) and the active form of caspase 4 (p20 kDa) (A) in lung homogenates obtained from patients with lung cancer. The lung ‘healthy’ portion of the same patient is identified with H, while the neoplastic one is identified with LC.

(10) FIG. 9B. Presence of the precursor (p46 kDa) and the active form of caspase-1 (p20 kDa) in lung homogenates of patients with lung cancer.

(11) FIG. 10. A. presence of the active portion of IL-1α in patients with cancer (LC) compared to healthy ones (H); FIG. 10 B. quantification by ELISA of IL-1α, expressed as pg/mg of lung tissue analysed, C. levels of IL-1β in homogenates of human lung, healthy and with lung cancer.

(12) FIG. 11. Immunoprecipitation experiments on lung homogenates, healthy (H) and with neoplastic lesion (LC). Caspase-4 binds the AIM2 inflammasome complex.

(13) FIG. 12. Flow Chart representing what is reported in the literature (A) compared to what has now be found by these authors (B). A. It is known that, as a result of infection with pathogens, the canonical inflammasome dependent caspase-1 pathway is activated. The release of pro-inflammatory cytokines such as IL-1β and IL-18 [NCBI accession numbers: mouse: NP_032386.1] (SEQ ID No. 13); human: [AAH07461.1 (SEQ ID No. 14)] provides a cascade of events that amplify the pro-inflammatory response, so that the host is able to promote the pathogen clearance. Conversely, in a tumor context, (B) caspase-11 in the mouse and caspase-4 in humans are involved in the induction of an inflammatory response, as a result of the priming of the AIM2-dependent inflammasome complex. This mechanism is activated in response to AIM2 recognition of hydroxylated nucleosides (8-OH-dG), markers of oxidative stress.

EXAMPLES

(14) Materials and Methods

(15) Murine Model of Lung Carcinoma.

(16) C57Bl/6 mice (Harlan Laboratories, Italy) and 129Sv mice, and caspase-1 and 11 knockout mice (Charles River Laboratories, Italy) (females of 6-8 weeks) were subjected to intratracheal (i.t.) instillation of a carcinogen, N-nitroso-N-methyl-urea (NMU), having alkylating and mutagenic activities (Damiani et al., 2008). NMU was administered three times every 7 days, according to the following administration schedule and dosage: day 0, 50 μg/mouse; day 8, 10 μg/mouse and day 15, 10 μg/mouse (FIG. 1). In some experiments, an anti-IL-1α antibody (Ab) (2 μg/rat i.p.; eBioscience, USA), or a caspase-1 inhibitor (Ac-Y-VAD-cmk: 10 ug/mouse i.p., Sigma Aldrich, USA), or an anti-caspase-11 antibody (10 ug/mouse, i.p.; Santa Cruz, USA) were administered to C57Bl/6 mice treated with NMU. The animals were sacrificed at different time points (3-7-30 days from the first NMU administration), according to the scheme shown in FIG. 1. The tumor lesion was expressed as the tumor lesion area/total lung area ratio.

(17) Human Samples of Lung Carcinoma.

(18) The human samples were obtained following thoracic surgery and lung resection in patients with stage III carcinoma of epithelioid origin, adenocarcinoma of the non-small cell lung cancer type. The healthy portion, indicated with H, was obtained from a lung portion macroscopically very far from the cancerous area. The human tissues were provided by the Department of Thoracic Surgery of the Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy (informed consent was obtained).

(19) Western Blotting Analysis.

(20) The murine lungs and the human samples were digested with a digestion solution consisting of collagenase (1 U/ml) and DNAse I (20 μg/ml). Following protein determination, the samples were loaded (50 μg/sample) on 12% polyacrylamide gel, then transferred on to a nitrocellulose membrane. Anti-caspase-4 (Santa Cruz, USA), anti-caspase-1 (Santa Cruz, USA), anti-caspase-11 (Santa Cruz, USA), anti-IL-1α (R&D Systems, UK) antibodies were used. The loading control was performed by GAPDH recognition.

(21) In another set of experiments, the human or murine homogenates were immunoprecipitated by using magnetic microbeads (Invitrogen, USA) capable of binding the primary antibody (caspase-11, or caspase-4, or AIM2) and the specific antigen. In a second phase, the co-localization of the target recognized by the primary antibody, with AIM2 or 8-OH-dG, was evaluated by using the appropriate antibodies in order to detect the presence or absence of AIM2 or 8-OH-dG.

(22) ELISA.

(23) Human and murine lung homogenates were tested for the presence of IL-1α and IL-1β, following the instructions provided by the kit manufacturer (eBioscience, USA) (informed consent was obtained).

(24) Immunohistochemistry Analysis.

(25) The left lobes of mice treated with NMU were fixed in OCT medium (TedPella Inc., Milan, Italy), then cut into 7-12 μm cryosections, and stained with hematoxylin & eosin (H&E) to highlight the morphological characteristics of the tissue to be correlated to the cryosections subjected to immunofluorescent staining for identifying K-Ras presence (Cell Signalling, UK) in the lung cancer lesion, and/or to cryosections subjected to immunohistochemical analyses according to the diaminobenzidine method (DAB) in order to detect the immune complexes consisting of Ki-67, tumor marker, (Invitrogen, Italy) with the secondary HRP antibody. The control isotype for Ki-67 (anti-rat IgG) was used as negative control.

(26) Statistical Analysis.

(27) The results are expressed as mean±SEM. The differences between the various groups were statistically analyzed using One Way ANOVA analysis and/or Student's t test, as appropriate. The p-values lower than 0.05 were considered statistically significant.

(28) Results

(29) 1. Caspase-11 is Involved in Lung Cancer Growth in the Mouse.

(30) In C57Bl/6 mice, the treatment with NMU produced tumor lesions, as indicated by the lung cryosections (FIG. 2A) that were positive for tumor proliferation markers, such as Ki-67 (FIG. 2B), and K-Ras (FIG. 2C). In mice treated with NMU, the tumor masses growth, calculated as the ratio between the tumor area and the total area, is of exponential type (FIG. 2D).

(31) A very interesting finding, object of the present invention, was the observation that the caspase-11 was active from day 3 after NMU administration up to 4 weeks (FIG. 3) compared to naïve mice (untreated) which did not show the active form of the enzyme (p20 kDa), but only the inactive form (p48 kDa).

(32) In order to highlight the role of caspase-11 in lung tumor growth, 129Sv mice, deficient in caspase-11 (Kayagaki et al., 2011) were used. 129Sv mice treated with NMU developed an extremely small tumor mass (7 days: 0.043±0.013; 30 days: 0.055±0.012) compared to C57131/6 mice receiving the same treatment (7 days: 0.101±0.013; 30 days: ±0.123 0.016) (FIG. 4A; **p<0.01; ***p<0.005). Furthermore, being caspase-11 involved in the release of alarmins, such as IL-1α (Ng and Monack, 2013), C57Bl/6 animals treated at the same time with NMU and with an anti-IL-1α antibody, showed a significant reduction of the tumor lesion (7 days: 0.056±0.013, p<0.05; 0.047±0.016, 30 days: p<0.005) (FIG. 4B), fully comparable to tumor development observed in 129Sv mice (7 days: 0.043±0.013; 30 days: 0.055±0.012) deficient in caspase-11. This finding strongly corroborates the role of caspase-11 in lung tumor growth in mice.

(33) Since it has been reported that caspase-11 can induce the activation of the non-canonical inflammasome pathway through caspase-1 activation (Case et al., 2013), we observed that also in our experimental model, the caspase-1 was activated at different time points (3-7-30 days) compared to naïve mice, as shown in FIG. 5B vs. 5A. It was also interestingly observed that caspase-1 was not activated in 129Sv mice treated with NMU (FIG. 5C), implying a close correlation between caspase-1 activity and the presence of functional caspase-11 in lung tumor growth.

(34) In support to this, mice genetically deficient in caspase-1 and caspase-11 (caspase-1/11 ko) showed a smaller tumor lesion (***p<0.0005, ****p<0.0001) compared to C57Bl/6 animals (FIG. 6A). Moreover, these data were comparable to those obtained in 129Sv animals exposed to NMU (FIG. 5C), thus implying that caspase-11 plays a pivotal role for lung carcinogenesis (FIG. 6B). Additionally, in support of the above statements, the C57Bl/6 animals exposed to NMU were treated with a known specific caspase-1 inhibitor (Ac-Y-VAD-cmk: y-VAD). As shown in FIG. 6C, the tumor lesion was reduced (*p<0.05, **p<0.01) in animals treated with y-VAD, although this injury was not comparable to that observed in caspase-1/11 ko and 129Sv mice (FIG. 6D). These data corroborate a main activity of caspase-11, that ‘orchestrate’ caspase-1 activity during lung carcinogenesis. Moreover, treatment of mice with an antibody capable of inhibiting caspase-11 activity significantly reduced (*p<0.05) the tumor mass compared to controls or treated animals with the control isotype (rabbit IgG) (FIG. 7).

(35) It is well known in the literature that caspase-11 is able to induce caspase-1 activation through NLRP3, one of the inflammasome components (Case et al., 2013). Since in our experimental model the activation of caspase-11 in C57Bl/6 (FIG. 3) is associated with active caspase-1 (FIG. 5), while in 129Sv mice, lacking of caspase-11, caspase-1 is not active (FIG. 5C), an immunoprecipitation analysis was performed on samples of lung homogenates from mice C57Bl/6, naïve and treated with NMU. This experiment was performed to determine the caspase-11 binding to inflammasome components, such as NLRP3 and AIM2. Western Blotting analyses show that caspase-11 is able to bind AIM2, but not NLRP3 (not revealed in this immunoprecipitation analysis: data not shown) (FIG. 8A). Moreover, it was observed that the activation of AIM2, that binds to caspase-1 (Schroder and Tschopp, 2010) and caspase-11 (as demonstrated herein), was induced by hydroxylated guanosine derivatives (8-OH-dG) (FIG. 8). Specifically, 8-OH-dG detection by Western Blotting on AIM2 immunoprecipitates of lung homogenates obtained from naïve or NMU-treated C57Bl/6 mice showed that 8-OH-dGs were bound to AIM2 in mice with lung tumor, compared to naïve mice (FIG. 8B). This finding has never been reported in the literature, and provides a new mechanism of action for caspase-11 involvement in the non-canonical inflammasome pathway during lung carcinogenesis in mice.

(36) 2. Caspase-4 is Active in Human Tumor Tissues of Lung Carcinoma.

(37) In order to make the present study translational, the role of the human analogue of caspase-11, i.e. caspase-4, was analyzed. The caspase-4 was active (p20 kDa) in all the tumor tissues analysed from 7 patients, as compared to healthy tissues (FIG. 9A). Moreover, in the same tissues, the caspase-1 was found to be activated (p20 kDa) more in the tumor portion than in the healthy one (FIG. 9B). Therefore, the presence of the activity of these enzymes in humans is similar to that observed in mice. In addition, IL-1α (FIGS. 10A and B, **p<0.005) and IL-1β (FIG. 10B, *p<0.05) presence was higher in the tumor tissues than in normal tissue. Similarly to what observed in the mouse, caspase 4 was associated with AIM2, as demonstrated by immunoprecipitation experiments followed by Western Blotting analyses performed on homogenate tissues of human healthy lung and lung with tumor lesions (FIG. 11).

(38) These data show for the first time that the active forms of the caspase proteins, particularly caspase-4 (in humans) and caspase-1, and of the proteins encoded by orthologous genes of the respective human caspases genes, in particular by the orthologue gene of the human caspase-4 gene, preferably caspase-11 (in the mouse), are involved in lung tumorigenesis.

(39) Compared to what is reported in the literature in the mouse (panel A of FIG. 12), the present authors have shown that, in addition to the role of caspase-11/4 in the tumor growth, the latter is in turn activated by AIM2 bound to 8-OH-DG, guanosine hydroxylated derivatives, which are a result of the oxidative stress underlying the inflammasome activation, which in turn may promote neoplastic growth induced by carcinogens (panel B of FIG. 12).

BIBLIOGRAPHY

(40) Allen, I. C., TeKippe, E. M., Woodford, R.-M. T., Uronis, J. M., Roll, E. K., Rogers, A. B., Herfarth, H. H., Jobin, C., and Ting, J. P.-Y. (2010). The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056. Bortoluci, K. R., and Medzhitov, R. (2010). Control of infection by pyroptosis and autophagy: role of TLR and NLR. Cell. Mol. Life Sci. CMLS 67, 1643-1651. Caffrey, D. R., and Fitzgerald, K. A. (2012). Select Inflammasome Assembly. Science 336, 420-421. Case, C. L., Kohler, L. J., Lima, J. B., Strowig, T., de Zoete, M. R., Flavell, R. A., Zamboni, D. S., and Roy, C. R. (2013). Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila. Proc. Natl. Acad. Sci. U.S.A. 110, 1851-1856. Chow, M. T., Sceneay, J., Paget, C., Wong, C. S. F., Duret, H., Tschopp, J., Möller, A., and Smyth, M. J. (2012a). NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 72, 5721-5732. Chow, M. T., Tschopp, J., Möller, A., and Smyth, M. J. (2012b). NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma. Immunol. Cell Biol. 90, 983-986. Coussens, L. M., Zitvogel, L., and Palucka, A. K. (2013). Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286-291. Damiani, L. A., Yingling, C. M., Leng, S., Roma, P. E., Nakamura, J., and Belinsky, S. A. (2008). Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalised bronchial epithelial cells. Cancer Res. 68, 9005-9014. Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., and Tschopp, J. (2008). Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677. Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., 25 Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009). Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15, 1170-1178. Jett, J. R., Cortese, D. A., and Fontana, R. S. (1983). Lung cancer: Current concepts and prospects. CA. Cancer J. Clin. 33, 74-86. 30 Kayagaki, N., Warming, S., Lamkanfi, M., Vande Walle, L., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011). Non-canonical inflammasome activation targets caspase-11. Nature 479, 117-121. Kayagaki, N., Wong, M. T., Stowe, I. B., Ramani, S. R., Gonzalez, L. C., Akashi-Takamura, S., Miyake, K., Zhang, J., Lee, W. P., Muszyński, A., et al. (2013). Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246-1249. Lamkanfi, M., and Dixit, V. M. (2012). Inflammasomes and their roles in health and disease. Annu. Rev. Cell Dev. Biol. 28, 137-161. Latz, E., Xiao, T. S., and Stutz, A. (2013). Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397-411. Ng, T. M., and Monack, D. M. (2013). Revisiting caspase-11 function in host defense. Cell Host Microbe 14, 9-14. 10 Paul-Clark, M. J., George, P. M., Gatheral, T., Parzych, K., Wright, W. R., Crawford, D., Bailey, L. K., Reed, D. M., and Mitchell, J. A. (2012). Pharmacology and therapeutic potential of pattern recognition receptors. Pharmacol. Ther. 135, 200-215. Pinto, A., Morello, S., and Sorrentino, R. (2011). Lung cancer and Toll-like receptors. Cancer Immunol. Immunother. CII 60, 1211-1220. Schroder, K., and Tschopp, J. (2010). The inflammasomes. Cell 140, 821-832. Valavanidis, A., Fiotakis, K., and Vlachogianni, T. (2008). Airborne particulate matter and human health: toxicological assessment and importance of size and composition of particles for oxidative damage and carcinogenic mechanisms. J. Environ. Sci. Health Part C Environ. Carcinog. Ecotoxicol. Rev. 26, 339-362. 20 Zitvogel, L., Kepp, O., Galluzzi, L., and Kroemer, G. (2012). Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13, 343-351. Yamauchi M. Yamaguchi R. et al., PLOS One, Vol. 7 (9), e43923-e43923 (2012).